Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Xiidra is positioned as the only Rx treating both signs and symptoms of dry eye, with a high FDA efficacy bar; Novartis framed the acquisition as strategic…
Bausch + Lomb agreed (announced June 30, 2023) to acquire Xiidra, libvatrep and AcuStream from Novartis for up to $2.5B: $1.75B upfront cash plus up to…
Novartis completed the divestment of Xiidra, SAF312/libvatrep, AcuStream and OJL332 to Bausch + Lomb on September 29, 2023 for USD 1.75B upfront plus up to USD…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Novartis agreed to acquire global rights to Takeda's Xiidra (lifitegrast) for dry eye disease for $3.4B upfront plus up to $1.9B in potential milestones (~$5.3B total). Strengthens Novartis' eye-care portfolio. Post-close outcome: Novartis subsequently exited the asset. On June 30, 2023 Bausch + Lomb agreed to acquire Xiidra (along with libvatrep/SAF312, the AcuStream delivery device, and pre-clinical OJL332) from Novartis for up to $2.5B (USD 1.75B upfront cash plus up to USD 750M in sales/commercialization milestones); the divestment completed September 29, 2023 — roughly four years after Novartis paid up to $5.3B for the product.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Xiidra (lifitegrast) from Takeda (this deal) | 2019 | $5.3B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · Novartis AG deals · Ophthalmology deals